Breaking News Instant updates and real-time market news.

NVS

Novartis

$94.18

-0.77 (-0.81%)

, AMGN

Amgen

$192.21

-0.74 (-0.38%)

16:08
04/04/19
04/04
16:08
04/04/19
16:08

Novartis announces legal dispute with Amgen regarding migraine collaboration

Novartis (NVS) announced that there is a legal dispute with Amgen (AMGN) regarding the collaboration agreements in the field of migraine. On April 2, Amgen issued a notice of termination of its migraine collaboration agreements with Novartis based on "an alleged material breach of the collaboration agreements." Novartis said in its statement that it "disputes the notice vigorously. In order to prevent an unjustifiable attempt by Amgen to end the collaboration, Novartis has filed a lawsuit asking the court to confirm that Amgen has no right to terminate the agreements." The agreements will remain in force unless and until a final and binding court decision is pronounced that terminates the agreements.

NVS

Novartis

$94.18

-0.77 (-0.81%)

AMGN

Amgen

$192.21

-0.74 (-0.38%)

  • 04

    Apr

  • 08

    Apr

  • 10

    Apr

  • 30

    Apr

NVS Novartis
$94.18

-0.77 (-0.81%)

02/20/19
MSCO
02/20/19
NO CHANGE
Target $215
MSCO
Overweight
Amgen could fall over 10% if Sandoz wins Enbrel IP case, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that a District Court verdict is expected some time in Q1 of 2019 on the ability of Novartis' (NVS) generics division Sandoz to launch their Enbrel biosimilar, Erelzi, which received FDA approval in mid-2016 but has been blocked by a preliminary injunction obtained by Amgen (AMGN). In a scenario where the court rules in favor of Amgen, he would expect upside of 3%-5% for Amgen shares and he would expect AbbVie (ABBV) to trade up 1%-2% in sympathy. If the court rules in favor of Sandoz, Harrison would expect downside of over 10% for Amgen and would expect AbbVie shares to trade down 6%-8%. If the companies announce a settlement, he would expect 1%-2% upside for Amgen and a minimal impact on AbbVie shares, Harrison tells investors. His base case view is that the ruling is likely to be in favor of Amgen, noted Harrison, who keeps an Overweight rating on Amgen.
02/25/19
BERN
02/25/19
NO CHANGE
BERN
Spark Therapeutics, Roche deal makes sense, says Bernstein
Bernstein analyst Vincent Chen notes that he has long seen Spark Therapeutics (ONCE) as a takeout candidate in gene therapy after the Wall Street Journal reported Roche (RHHBY) is near acquiring the company for close to $5B. The analyst thinks the deal makes sense as adding hemophilia gene therapy to Hemlibra sets up Roche as a leader in next-gen non-factor hemophilia drugs, CNS gene therapy pipeline is a good fit for Roche's growing neuroscience franchise, and as it serves as a cornerstone in establishing Roche as a gene therapy leader, to rival the likes of Novartis (NVS).
03/04/19
PIPR
03/04/19
NO CHANGE
PIPR
Piper Jaffray sees continued medical cannabis growth
Piper Jaffray analyst Michael Lavery writes that his discussions with a medical pain specialist in New York affirm his expectations of continued growth for medical cannabis, particularly as practitioners search for opioid alternatives. With over 30 U.S. states now in favor of medical use of marijuana, the analyst believes that the national prohibition will end in the next few years with the "STATES Act or federal legalization". Lavery is positive on Tilray (TLRY) and its partnership with Novartis (NVS) to develop and distribute medical cannabis products, keeping his Overweight rating and $90 price target on the shares. The analyst also calls GW Pharma (GWPH) a "trailblazer for developing cannabis-derived products for medical use", with its FDA-approved epidiolex cannabidiol product, keeping his Overweight rating and $195 price target on the stock. Lavery further maintains his Overweight rating and $60 price target on Canopy Growth (CGC) given its current valuation.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
AMGN Amgen
$192.21

-0.74 (-0.38%)

02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
03/14/19
BMOC
03/14/19
INITIATION
Target $228
BMOC
Outperform
Amgen initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Amgen with an Outperform and $228 price target. Kim views shares are undervalued, and said concerns over the declining legacy franchises have overshadowed the emergent early lifecycle commercial drugs and promising late- and early-stage pipeline. The analyst views Amgen as a core biotech holding, as a stable dividend and aggressive stock buybacks provide a defensive investment, with meaningful pipeline opportunities for long-term growth.
03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Inovio d-BiTEs news a 'significant pleasant surprise,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said Inovio (INO) presented what he considers interesting, "albeit preclinical," data on DNA-encoded bispecific T-cell engagers, or "d-BiTEs," that could offer the advantages of Amgen's (AMGN) BiTE technology while "also offering what we see as an elegantly simple approach to addressing the inherent half-life challenges of current BiTE technology." Raymond said he did not expect that the company would be working on DNA-encoded bispecifics and called the announcement "a significant pleasant surprise" from the American Association for Cancer Research Annual Meeting. Raymond keeps an Overweight rating on Inovio shares.

TODAY'S FREE FLY STORIES

LPL

LG Display

$8.35

-1.14 (-12.02%)

12:10
04/24/19
04/24
12:10
04/24/19
12:10
Downgrade
LG Display rating change  »

LG Display downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$60.91

-1.44 (-2.31%)

, APC

Anadarko

$71.89

7.77 (12.12%)

12:09
04/24/19
04/24
12:09
04/24/19
12:09
On The Fly
Fly Intel: Wall Street's top stories at midday »

The major averages are…

OXY

Occidental Petroleum

$60.91

-1.44 (-2.31%)

APC

Anadarko

$71.89

7.77 (12.12%)

CVX

Chevron

$118.80

-3.2 (-2.62%)

BA

Boeing

$378.71

4.67 (1.25%)

T

AT&T

$30.75

-1.36 (-4.24%)

CAT

Caterpillar

$138.18

-3.9 (-2.74%)

CBS

CBS

$51.44

0.09 (0.18%)

VIA

Viacom

$36.81

0.53 (1.46%)

VIAB

Viacom

$29.88

0.61 (2.08%)

SAP

SAP

$127.96

13.12 (11.42%)

SLAB

Silicon Labs

$105.83

12.195 (13.02%)

EBAY

eBay

$38.25

1.59 (4.34%)

RES

RPC, Inc.

$11.10

-1.8 (-13.95%)

IRBT

iRobot

$103.20

-27.22 (-20.87%)

SNAP

Snap

$11.36

-0.63 (-5.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 26

    Apr

  • 29

    Apr

  • 30

    Apr

  • 02

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 10

    May

  • 10

    May

  • 14

    May

  • 14

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 24

    Jul

  • 13

    Nov

TDOC

Teladoc

$54.67

0.32 (0.59%)

, HUM

Humana

$249.01

0.71 (0.29%)

12:09
04/24/19
04/24
12:09
04/24/19
12:09
Recommendations
Teladoc, Humana analyst commentary at Baird »

Humana virtual primary…

TDOC

Teladoc

$54.67

0.32 (0.59%)

HUM

Humana

$249.01

0.71 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 22

    May

  • 23

    May

  • 05

    Jun

  • 13

    Nov

MPC

Marathon Petroleum

$60.06

-0.94 (-1.54%)

12:05
04/24/19
04/24
12:05
04/24/19
12:05
Options
Marathon Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 08

    May

UMC

UMC

$1.94

0.015 (0.78%)

12:04
04/24/19
04/24
12:04
04/24/19
12:04
Upgrade
UMC rating change  »

UMC upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

LRN

K12

$31.56

-4.665 (-12.88%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
K12 falls -12.4% »

K12 is down -12.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$4.28

-0.685 (-13.80%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
Superior Energy falls -13.9% »

Superior Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

RES

RPC, Inc.

$11.04

-1.86 (-14.42%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
RPC, Inc. falls -14.2% »

RPC, Inc. is down -14.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 08

    May

  • 09

    May

  • 13

    Nov

SAP

SAP

$128.22

13.38 (11.65%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
SAP rises 11.7% »

SAP is up 11.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 07

    May

APC

Anadarko

$71.92

7.8 (12.16%)

12:00
04/24/19
04/24
12:00
04/24/19
12:00
Hot Stocks
Anadarko rises 12.4% »

Anadarko is up 12.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

TRK

Speedway Motorsports

$18.50

4.52 (32.33%)

12:00
04/24/19
04/24
12:00
04/24/19
12:00
Hot Stocks
Speedway Motorsports rises 32.8% »

Speedway Motorsports is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

12:00
04/24/19
04/24
12:00
04/24/19
12:00
General news
Treasury Action: Fed funds futures are rallying alongside the surge in Treasuries »

Treasury Action: Fed…

HMST

HomeStreet

$28.08

(0.00%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Hot Stocks
HomeStreet 'disappointed' over Blue Lion's director nominations, proposals »

HomeStreet issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

PYPL

PayPal

$107.92

1.01 (0.94%)

, FB

Facebook

$183.84

0.07 (0.04%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Earnings
Fly Intel: What to watch in PayPal earnings report »

PayPal (PYPL) is…

PYPL

PayPal

$107.92

1.01 (0.94%)

FB

Facebook

$183.84

0.07 (0.04%)

EBAY

eBay

$38.45

1.79 (4.88%)

JPM

JPMorgan

$113.45

-0.29 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 09

    May

  • 14

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 11

    Jun

  • 16

    Jul

AMRN

Amarin

$18.32

-0.07 (-0.38%)

11:45
04/24/19
04/24
11:45
04/24/19
11:45
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 06

    May

11:45
04/24/19
04/24
11:45
04/24/19
11:45
General news
Treasury's $20 B FRN auction was awarded at a high discount margin of 0.139% »

Treasury's $20 B FRN…

LRN

K12

$31.11

-5.115 (-14.12%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Recommendations
K12 analyst commentary at Barrington »

Barrington reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$262.87

-0.98 (-0.37%)

, SSNLF

Samsung

$0.00

(0.00%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Earnings
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

TSLA

Tesla

$262.87

-0.98 (-0.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

CAT

Caterpillar

$138.82

-3.26 (-2.29%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar: Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

GWW

Grainger

$292.75

-0.46 (-0.16%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Grainger authorizes repurchase of additional 5M shares »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BKU

BankUnited

$35.97

0.24 (0.67%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Downgrade
BankUnited rating change at Sandler ONeill »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 15

    May

GWW

Grainger

$292.73

-0.48 (-0.16%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Hot Stocks
Grainger raises dividend by 6% to $1.44 per share »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BBY

Best Buy

$75.08

1.48 (2.01%)

, PG

Procter & Gamble

$104.47

1.28 (1.24%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
On The Fly
Best Buy, P&G, Snap upgrades among today's top analyst calls »

Check out today's top…

BBY

Best Buy

$75.08

1.48 (2.01%)

PG

Procter & Gamble

$104.47

1.28 (1.24%)

SNAP

Snap

$11.20

-0.79 (-6.59%)

KHC

Kraft Heinz

$32.73

-0.365 (-1.10%)

AAPL

Apple

$208.23

0.73 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 23

    May

  • 29

    May

  • 03

    Jun

TEVA

Teva

$14.98

0.07 (0.47%)

, MYL

Mylan

$26.47

-0.13 (-0.49%)

11:35
04/24/19
04/24
11:35
04/24/19
11:35
Recommendations
Teva, Mylan, Novartis analyst commentary at Wells Fargo »

Sandoz results should not…

TEVA

Teva

$14.98

0.07 (0.47%)

MYL

Mylan

$26.47

-0.13 (-0.49%)

NVS

Novartis

$78.35

2.51 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 08

    May

  • 22

    May

  • 31

    May

YPF

YPF

$14.54

-0.35 (-2.35%)

11:35
04/24/19
04/24
11:35
04/24/19
11:35
Options
YPF put volume heavy and directionally bearish »

Bearish flow noted in YPF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.